OptMed is an advanced-stage biomaterials company developing proprietary polymer-based products in the areas of tissue repair and drug delivery. The company’s initial focus is on a new class of surgical adhesives and a locally delivered therapeutic to treat painful bladder syndrome associated with interstitial cystitis. The company’s surgical adhesive program is expected to generate an initial 510(k) application for approval of a topical product and initiate clinical development of a second product for internal use in 2009. The interstitial cystitis therapy is positioned to enter clinical studies and generate key data in 2009.